Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 12/20 | 0.42 |
| ▸ | PPARA | Q07869 | 11/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138333 | 0.76 | HTR6 (0.45) | ALDH1A1GAAMAPT | |
| SCHEMBL6500263 | 0.76 | FFAR1 (0.45) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL6500269 | 0.75 | FFAR1 (0.44) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL6489153 | 0.73 | PPARD (0.53) | ALDH1A1PPARDPPARAPPARGFFAR1 | |
| SCHEMBL11926060 | 0.72 | NPC1 (0.56) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL6502357 | 0.72 | FFAR1 (0.48) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL5657706 | 0.72 | PPARD (0.55) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL1553917 | 0.71 | NPC1 (0.54) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL3822273 | 0.71 | NPC1 (0.58) | NPC1ALDH1A1GAAPPARDPPARA | |
| SCHEMBL5015456 | 0.71 | NPC1 (0.54) | NPC1ALDH1A1GAAPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005060958-A1 | (5- (2-PHENYL)-THIAZOL-5-YLMETHOXY)-INDOL-1-YL) -ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE HUMAN PPAR-DELTA RECEPTOR FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS TYPE 2 DIABETES | KALYPSYS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |